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At the European Society of Cardiology (ESC) congress of this year 2019, held in Paris from
August 31st to September 4th, 4509 abstracts were presented. Of those, 414 (9%) belonged to an
imaging category. Experts in echocardiography (VD), nuclear imaging (AS), cardiac computed
tomography (CT) (MD) and cardiovascular magnetic resonance (CMR) (CBD), have selected
the abstracts in their areas of expertise that were of most interest to them and are summarized
in this bird’s eye view from this ESC meeting. These abstracts were integrated by one of the
Editors of the Journal (JB). (J Nucl Cardiol 2020;27:53–61.)
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Abbreviations
CAD Coronary artery disease
CMR Cardiac magnetic resonance
CRT Cardiac resynchronization therapy
CT Computed tomography
CTCA Computed tomography coronary
angiography
ECV Extracellular volume
ESC European Society of Cardiology
FAI Fat attenuation index
FDG Fluorodeoxyglucose
HRP High-risk plaque
LGE Late gadolinium enhancement
LV Left ventricular
LVEF Left ventricular ejection fraction
PET Positron emission tomography
SPECT Single-photon emission computerized
tomography
STEMI ST-segment elevation myocardial
infarction
ECHOCARDIOGRAPHY
The new guidelines on chronic coronary syn-
dromes,1 dyslipidemia2 and diabetes mellitus3 include
recommendations on the use of imaging for diagnosis
and risk stratification of atherosclerotic cardiovascular
disease. Detection of carotid atherosclerotic plaque with
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carotid ultrasound is a modifier of the risk of
atherosclerotic cardiovascular disease. In 415 women
(62 ± 10 years old, 28% with diabetes mellitus)
undergoing stress echocardiography, Gurunathan
et al4 evaluated the incremental value of carotid
ultrasound to detect significant coronary artery disease
(CAD). Inducible wall motion abnormalities were
detected in 47 (11%) women and 41% presented
carotid plaque while carotid intima media thickness
[ 75th percentile was measured in 15%. Stress
echocardiography had a positive predictive value of
51% for detecting [ 70% coronary artery stenosis on
invasive coronary angiography and improved to 71%
when carotid plaque was present. These results have
important clinical implications since it is well known
that the unique pathophysiological mechanisms causing
ischemia and the lower prevalence of significant CAD
in women limit the predictive value of conventional
stress testing techniques.
Mitral annulus disjunction, defined as a variation in
the attachment of the posterior mitral leaflet character-
ized by a wide separation between left atrial wall and the
left ventricular (LV) free wall, is frequently observed in
patients with mitral valve prolapse. In a large series of
patients with moderate and severe mitral regurgitation
due to mitral valve prolapse, Mantegazza et al5
described a frequency of mitral annulus disjunction of
21% among 630 patients with Barlow’s disease, which
is lower than previously reported. In addition, the series
included 349 patients with fibroelastic deficiency in
whom the presence of mitral annulus disjunction was
observed in 8%. Patients with mitral annulus disjunction
were usually younger, had more dilated mitral annulus
and more frequently presented bileaflet prolapse as
compared to patients without.
Assessment of LV systolic function after ST-seg-
ment elevation myocardial infarction (STEMI) has
important clinical implications. Speckle tracking
echocardiography has provided various parameters that
have incremental prognostic value over conventional LV
ejection fraction. In 372 patients with STEMI treated
with primary percutaneous coronary intervention, Brai-
nin et al6 measured early systolic lengthening from
speckle tracking derived longitudinal strain. The early
systolic lengthening is an index that reflects myocardial
viability and is calculated as (100 9 [peak positive
systolic strain/peak negative global strain]) and averaged
for 18 LV myocardial segments. In the segments
supplied by the infarct-related artery, the early systolic
lengthening was significantly higher than in the remote
segments (6.7 ± 6.2% vs 5.0 ± 4.1%, P\ .001). During a
median follow-up of 5 years, 39% of patients reached
the composite primary end-point of incident heart
failure, myocardial infarction or all-cause mortality.
Each 1% increase in early systolic lengthening was
associated with 27% increased risk of the composite
primary end-point.
Other measures of LV myocardial performance that
have been presented at this ESC congress were cardiac
power output-to-mass ratio and speckle tracking derived
myocardial work indices. In 24,783 patients with pre-
served LV ejection fraction (C 50%) undergoing
exercise echocardiography, Anand et al7 evaluated the
prognostic relevance of peak exercise cardiac power
output-to-mass ratio and power reverse (increase in
cardiac power output-to-mass ratio from rest to peak
exercise). Patients with significant valvular heart disease
or right ventricular systolic dysfunction were excluded.
Cardiac power output-to-mass ratio is calculated as
(0.222 9 cardiac output x mean blood pressure/LV
mass) and expressed in Watts/100 g myocardium.
Lower peak exercise cardiac power output-to-mass ratio
and power reserve were independently associated with
increased risk of all-cause mortality. Patients within the
lowest power reserve quartile (\ 0.95 W/100 g) but with
otherwise normal stress test had similar survival as those
with ischemia on stress test or ischemic cardiomyopa-
thy. In patients with heart failure treated with cardiac
resynchronization therapy, regional measures of
myocardial work based on speckle tracking echocardio-
graphy provide further insights into the response to the
device therapy. Regional LV myocardial work is calcu-
lated by integrating non-invasive blood pressure
measurements, timing of mitral and aortic valve opening
and closure and speckle tracking derived LV longitudi-
nal strain. The pressure-strain loops are then derived and
the constructive work and wasted work are calculated.
Kostyukevich et al8 demonstrated that immediately after
cardiac resynchronization therapy implantation, respon-
ders (patients who showed at 6 months follow-up LV
reverse remodeling) showed improvement in construc-
tive work (433.0 [254.5;686.5] mmHg% to 664.5
[424.5;977.8] mmHg%; P \ .001) and wasted work
(305.0 [169.0;461.3] mmHg% to 145.0 [80.0;306.3]
mmHg%; P = .005) of the septal wall whereas the lateral
wall showed normalization of the constructive work
with slight increase in wasted work (Figure 1). In
contrast, non-responders only showed a decrease in the
wasted work of the septal wall.
Based on 3-dimensional echocardiography, the
geometry and function of the right ventricle can be
fully appreciated. Kovacs et al9 described the compo-
nents of the right ventricular function in 231 healthy
individuals: the longitudinal and radial ejection fraction
contribute equally to the global right ventricular ejection
fraction whereas the anteroposterior ejection fraction has
less contribution. Interestingly, the anteroposterior ejec-
tion fraction showed a decline with age. The relative
54 Bax et al Journal of Nuclear Cardiology
Multimodality imaging: Bird’s eye view from the European Society of Cardiology Congress 2019 January/February 2020
contributions of each ejection fraction to the global right
ventricular ejection fraction in pathological situations
needs to be elucidated in future studies.
NUCLEAR IMAGING
Machine learning may be helpful in interpretation
of imaging data through complex data-pattern recogni-
tion. The study of Hu et al10 aimed to develop a machine
learning computer score derived from stress imaging and
clinical data, which indicates if the rest scan could be
automatically canceled during myocardial perfusion
imaging. The study population consisted of 20,414
patients from the REFINE SPECT registry who had
undergone rest/stress single-photon emission computer-
ized tomography (SPECT). There were 3542 adverse
events including revascularization, death, myocardial
infarction or unstable angina during 4.7 years of follow-
up. Machine learning could be used to automatically
cancel the rest myocardial perfusion scan with the same
proportion (60%) as using normal visual reading, but
with significantly lower rate of adverse events after
stress-only scan (annual rate 1.5% vs 2.1%) indicating
that the rest scan could be safely canceled based on
machine learning. Juarez-Orozco et al11 evaluated the
feasibility and performance of deep learning survival
analysis in predicting outcomes in a registry of 951
patients with suspected CAD who underwent cardiac
hybrid positron emission tomography/computed tomog-
raphy (PET/CT). Cox-Nnet (a deep survival neural
network) evaluation of PET perfusion and CT angiog-
raphy data outperformed categorical expert
interpretation and coronary calcium score (c-index =
0.75, 0.54 and 0.65, respectively) in predicting the
occurrence of myocardial infarction or death during
follow-up. The authors conclude that deep learning
survival analysis is feasible in the evaluation of
Figure 1. Changes in regional left ventricular myocardial work in responder (A) and non-
responder (B) to cardiac resynchronization therapy. The pressure-strain loops are shown for the
global left ventricular (LV) cardiac constructive work (CW) (in red) and for the indicated segments
(in green). In the responder patient (A), after implantation of cardiac resynchronization therapy
there is an increase in the LV CW and this is achieved by significant improvement in CW of the mid
septal segment and normalization of the CW of the mid lateral segment. In the non-responder
patient (B), the CW of the mid septal segment improves but the lateral wall remains impaired
resulting in reduced LV CW. Reproduced with permission from Kostyukevich et al8 bl, baseline; pi,
post-implantation; WW, wasted work.
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cardiovascular prognostic data and may facilitate pre-
diction of outcomes.
18F-sodium fluoride (18F-NaF) PET provides an
opportunity to assess microcalcification in the coronary
arteries. Doris et al12 evaluated the relationship between
coronary 18F-NaF uptake and progression of coronary
calcification in 185 patients with multivessel CAD
(Figure 2). Patients with coronary 18F-NaF uptake at
baseline (n = 116) demonstrated more rapid progression
of coronary calcification during 1 year of follow-up than
patients without 18F-NaF uptake [change in Agatston
score 97 (39-166) vs 35 (7-93), P\ .001]. The authors
conclude that 18F-NaF PET not only identifies patients
with more advanced coronary calcification, but also
patients with rapid progression of coronary calcification
during 1-year.
The value of hybrid 18F-fluorodeoxyglucose (18F-
FDG) PET and CMR in predicting recovery of wall
motion after percutaneous coronary intervention of
chronic total coronary occlusion was studied by Vita-
dello et al.13 In 49 patients with chronic total coronary
occlusion and wall motion abnormality in the corre-
sponding coronary territory, almost one third of the
dysfunctional segments showed discordant imaging
findings: 4% were non-viable by 18F-FDG-PET, but
viable by CMR, whereas 26% were viable by 18F-FDG
PET, but non-viable by CMR. The combination of PET
and MR showed better accuracy in predicting
improvement of regional wall motion after revascular-
ization of chronic total coronary occlusion than either
18F-FDG PET or CMR alone (area under ROC curve
0.72, 0.58 and 0.66, P = .002). These results suggest that
hybrid PET/CMR may identify small amounts of viable
myocardium in scarred segments that are capable of
improving function after revascularization. In addition to
viable myocardium, 18F-FDG-PET can be used to detect
active cardiac inflammation after suppression of physi-
ological myocardial glucose uptake. The study by
Protonotarios et al14 evaluated 18F-FDG PET in 18
patients with an arrhythmogenic cardiomyopathy diag-
nosed according to the 2010 Task Force criteria. 18F-
FDG uptake was common in patients with desmosomal
gene positive arrhythmogenic cardiomyopathy and clin-
ically active disease. All cases with 18F-FDG uptake
showed gadolinium late-enhancement, but they were
spatially discordant suggesting that 18F-FDG PET and
CMR provide complementary information on tissue
characterization also in arrhythmogenic cardiomyopathy.
18F-FDG PET has been shown to be useful for the
diagnosis of infective endocarditis, but its prognostic
value is unknown. Sovannarith et al15 evaluated the
prognostic value of 18F-FDG PET/CT in patients with
definitive prosthetic valve endocarditis (n = 109) or
native valve endocarditis (n = 64) during one-year of
follow-up. Valvular uptake of 18F-FDG was present in
82% of patients with prosthetic valve endocarditis and it
Figure 2. 18F-sodium fluoride positron emission tomography to predict progression of coronary
calcification. Examples of two patients undergoing 18F-sodium fluoride (18F-NaF) positron
emission tomography (PET) and coronary computed tomography angiography at baseline and
follow-up. The patient showing uptake of 18F-NaF (18F-fluoride positive) had progression of
coronary calcification at follow-up whereas the patient without uptake (18F-fluoride negative) did
not show changes. Reproduced with permission from Doris et al12.
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was associated with higher rate of a composite end-point
of death, recurrence of infective endocarditis, acute
cardiac failure, cardiovascular hospitalization, and new
embolic event (odds ratio = 2.6, 95% confidence interval
1.04-6.6, P = .04). In native valve endocarditis, valvular
18F-FDG uptake was not associated with the composite
end-point. However, 18F-FDG uptake graded as moder-
ate or high vs. absent or mild was predictive of embolic
events in both prosthetic and native valve endocarditis.
Therefore, 18F-FDG PET/CT is predictive of major
cardiac events in prosthetic valve endocarditis and
embolic events in both prosthetic and native valve
endocarditis during the first year following infective
endocarditis.
COMPUTED TOMOGRAPHY
Computed tomography coronary angiography
(CTCA) gained a class I recommendation for the
assessment of stable patients with chest pain in the
2019 ESC guidelines launched in Paris.1 Concerns have
been expressed that the widespread use of CTCA would
lead to an increased rate of invasive coronary angiog-
raphy. Weir-McCall et al16 examined trends in the use of
imaging for the investigation of CAD in England before
and after the 2016 National Institute for Clinical
Excellence (NICE) guidelines. These recommended
CTCA as the first line imaging test in patients with
chest pain. Importantly the NICE guidelines resulted in a
fall, not an increase in invasive coronary angiography
despite increased rates of CTCA. In addition, centers
with the greatest growth in CTCA had the greatest fall in
SPECT utilization so that overall imaging costs were
unchanged.
There was a clear focus at ESC 2019 on CT studies
examining coronary plaque and pericoronary fat. Dese-
ive et al17 measured the total coronary plaque volume
(both calcific and non-calcific) on CTCA in 1577
patients and then followed them up for 10.4 years for
the primary end-point of cardiac death and acute
coronary syndrome. The primary end-point was met in
59 patients. Total plaque volume provided incremental
prognostic information to a model incorporating cardio-
vascular risk factors and the severity of obstructive
CAD, whereas CT calcium scoring did not. This study
highlights the important prognostic role that measures of
total coronary plaque volume on contrast CT angiogra-
phy might play in clinical practice and highlights their
potential advantages compared to CT calcium scoring.
In a hybrid PET and CT study, Kwiencinski et al18
investigated the relationship of low-density plaque on
CT with uptake of the PET tracer 18F-NaF. Detailed
analysis of the coronary plaque composition and 18F-
NaF activity was performed in 20 patients undergoing
hybrid PET/CT coronary angiography. They demon-
strated that coronary vessels with increased 18F-NaF
activity had higher non-calcific and low-density plaque
volumes. Moreover, low-density plaque volume was an
independent predictor of 18F-NaF activity. This study
supports the hypothesis that patients with low-density
plaque have increased coronary plaque activity, which
might explain the increased event rate observed in these
patients.
Commandeur et al19 used machine learning to
perform fully automated quantification of the epicardial
adipose tissue in 850 non-contrast calcium scoring CT
scans. Automated quantification took less than 2 seconds
and demonstrated close agreement to epicardial adipose
volumes measured manually by experts who took 15
minutes. The same investigational group also used a
machine learning approach to determine whether CT
calcium scores and epicardial fat volumes (quantified
automatically using the above method) alongside clin-
ical information might improve risk prediction in 2071
patients from the EISNER trial.20 After long-term
follow-up they demonstrated that a machine learning
approach integrating clinical and quantitative imaging-
based variables improved the prediction of myocardial
infarction and cardiac death in patients undergoing CT
calcium scoring compared to standard risk assessment
methods.
Finally, Oikonomou et al21 investigated the com-
position of pericoronary fat on contrast CTCA as a
marker of coronary plaque inflammation and assessed its
prognostic value alongside high-risk coronary plaque
features assessed on the same scan. The rationale for this
approach is that atherosclerotic inflammation alters the
structure of the pericoronary fat by reducing its fat
content: an effect that can be captured using the
perivascular Fat Attenuation Index (FAI) (Figure 3,
panel A). The authors investigated 3912 patients from
the CRISP-CT study that had undergone clinically
indicated CTCA. High-risk plaque (HRP) was defined
as the presence of 1 or more of the following: positive
remodeling, low-attenuation plaque, spotty calcification
or napkin ring sign. After 5.6 years of follow-up, there
were 91 confirmed major adverse cardiovascular events
(cardiac mortality or non-fatal myocardial infarction)
(Figure 3, panel B). Patients with both HRP and high
FAI had a 6.3-fold higher adjusted risk of major adverse
cardiovascular events compared to individuals with
neither feature. Patients without HRP but a high FAI
had a 4.9-fold higher adjusted risk of major adverse
cardiovascular events. However, in patients with low
FAI, there was no significant difference in the prospec-
tive risk of major adverse cardiovascular events between
patients with and without HRP. These data indicate that
CTCA-derived FAI can improve patient risk
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stratification, supplementing anatomical plaque assess-
ments with a functional marker of disease activity.
CARDIOVASCULAR MAGNETIC RESONANCE
Non-invasive functional imaging for myocardial
ischemia, such as stress CMR, to diagnose CAD remains
as class IB recommendation in current ESC guidelines.
In this ESC congress, several abstracts provided addi-
tional information on the use of this imaging modality in
patients with suspected or known CAD. Haberkorn
et al22 performed a rigorous systematic review and meta-
analysis to compare the diagnostic accuracy of vasodila-
tor stress perfusion CMR and dobutamine stress
echocardiography using coronary angiography (coronary
stenosis[ 70%) or fractional flow reserve (\ 0.80) as a
reference standard for obstructive CAD. Of 5634 stud-
ies, 47 prospective studies were selected, totalling 4742
patients. The sensitivity, specificity and diagnostic odds
ratio for vasodilator stress CMR were 0.88 (95% CI)
0.850.90), 0.84 (95% CI 0.810.87), and 38 (95% CI
2949), and for dobutamine stress echocardiography 0.72
(95% CI 0.610.81), 0.89 (95% CI 0.830.93), and 20
(95% CI 946), respectively. Vasodilator stress CMR
refined the post-test probability of CAD based on lower
positive and negative likelihood ratios as compared to
dobutamine stress echocardiography (5.5 and 0.14 vs 6.3
and 0.3, respectively). On behalf of the GadaCAD
writing group, Andrew Arai presented the diagnostic
accuracy of gadobutrol-enhanced CMR to detect signif-
icant CAD combing the results of the GadaCAD1 (n =
376 patients) and GadaCAD2 (n = 389 patients) phase
III clinical trials.23 Three blinded, core-lab CMR readers
per trial (6 observers in total) and 2 core-lab readers of
quantitative coronary analysis participated in the anal-
ysis. The results showed that the test had 79%
sensitivity, 87% specificity, and area under the curve
of 0.82 to detect a 70% coronary artery stenosis on
quantitative coronary analysis. When a 50% stenosis
threshold was used, the area under the curve decreased
to 0.77 and the minimum performance threshold was
achieved in 1 out of the 6 readers for sensitivity (the
Figure 3. Assessment of high-risk plaque features and coronary inflammation on computed
tomography coronary angiography and prediction of major adverse cardiac events. (A) Shows the
high-risk plaque features (HRP) combined with the assessment of perivascular fat attenuation index
(FAI). (B) shows the Kaplan Meier curves for occurrence of major adverse cardiovascular events;
patients with HRP features and coronary inflammation based on FAI had significantly worse
prognosis as compared to the other groups of patients. Reproduced with permission from
Oikonomou et al21.
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lower limit of the 95% CI should be[ 60%) and in all
the observers for the specificity (the lower limit of the
95% CI should be [ 55%). Therefore, these results
support the 70% coronary stenosis threshold to define
hemodynamically significant stenosis.
Furthermore, stress CMR is an important imaging
tool for risk stratification of patients with known or
suspected CAD. In a prospective multicentre registry
including 6389 patients, Marcos Garces et al24 evaluated
the association between the ischemic burden and all-
cause mortality. During a median follow-up of almost 6
years, 717 (11.2%) patients died. The extent of ischemic
burden (per 1 segment increase) on vasodilator stress
CMR was independently related to long-term all-cause
death (HR 1.05 [95% CI 1.031.07], P\ .001). The
interaction between coronary revascularization and
vasodilator stress CMR was evaluated in 1034 patients
(517 revascularized and 517 non-revascularized strictly
1:1 matched for age, diabetes mellitus, male sex, LVEF,
ischemic burden and necrosis extent). In patients with
more than 5 ischemic LV segments, revascularization
was associated with improved survival (mortality rates
for revascularized and non-revascularized patients: 9.3%
vs. 16.3%, respectively: HR 0.56 [95% CI 0.320.98], P
= .02) but independently increased the risk in patients
with B5 ischemic LV segments (mortality rates for
revascularized and non-revascularized patients: 16.2%
vs 11.3%, respectively: HR 1.59 [95% CI 1.032.45],
P = .037).
In the field of valvular heart disease, the use of
CMR is increasing. Everett et al25 investigated the
association between the presence and extent of focal and
diffuse LV myocardial fibrosis with the disease severity
and long-term clinical outcome in 440 patients (70 ± 10
years, 59% male) with severe aortic stenosis scheduled
for aortic valve intervention. LV myocardial fibrosis was
quantified using CMR imaging with late gadolinium
enhanced and T1 mapping techniques (Figure 4). Extra-
cellular volume fraction [ECV%] calculated from T1
mapping images (mean 27.7 ± 3.6%) correlated signif-
icantly with lower peak aortic jet velocity, larger LV
mass, lower LVEF, and presence of late gadolinium
enhancement. Furthermore, ECV independently associ-
ated with all-cause mortality following adjustment for
age, sex, impaired LV ejection fraction and presence of
late gadolinium enhancement (HR per unit increase in
ECV: 1.10, 95%, (95% CI 1.021.19), P = .013). The
authors concluded that diffuse LV myocardial fibrosis
(ECV) correlates with LV dysfunction and it is a strong
independent predictor of late all-cause mortality.
Romano et al26 investigated whether LV GLS
measured with CMR feature tracking has prognostic
Figure 4. Comprehensive CMR assessment in valvular heart disease: ventricular function (A), late
gadolinium assessment (B), native T1 mapping (C), post-contrast T1 mapping (D) and extracellular
volume of distribution map (E). Reproduced with permission from Everett et al25.
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value in individuals with preserved LVEF. Consecutive
patients (n = 1274) with preserved LVEF ([ 50%) and a
clinical indication for CMR were included in a multi-
center American registry. The median value of LV GLS
was - 20%. During a median follow-up of 6.2 years,
115 patients died. Patients with an LV GLS C - 20%
had significantly reduced event-free survival compared
to those with GLS\- 20% (log-rank P\ .001). On Cox
multivariable regression, each 1% worsening in LVGLS
was associated with a 23.6% increased risk of death after
adjustment for clinical and imaging risk factors.
Finally, Menacho Medina et al27 presented the
effort of 4 countries (Argentina, Peru, India and South
Africa) and 12 centers to implement an educational
program and rapid CMR acquisition protocol (cardiac
anatomy, function and tissue characterization) in 510
patients with cardiomyopathy. The mean duration was
21 ± 6 minutes for a contrast study and 12 ± 3 minutes
for a non-contrast study. The measured clinical impact
of CMR was (a) identification of new diagnosis in 105
patients (21%), (b) change/addition of medication in 128
patients (25%), (c) new procedure (intervention/surgery
in 31 patients, 6% and invasive angiography or biopsy in
25 patients, 5%), or (d) hospital discharge/admission in
15 patients (3%). The investigators concluded that CMR
can be easily be delivered in the developing countries
with existing technology using faster protocols, leading
to a significant clinical impact in 60% of patients.
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